AMICUS THERAPEUTICS INC (FOLD)

US03152W1099 - Common Stock

11.86  -1.02 (-7.92%)

Premarket: 12.03 +0.17 (+1.43%)

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (9/28/2023, 7:00:00 PM)

Premarket: 12.03 +0.17 (+1.43%)

11.86

-1.02 (-7.92%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/bmo
Ins Owners1.33%
Inst Owners107.98%
Market Cap3.41B
Shares287.12M
PEN/A
Fwd PE87.21
Dividend YieldN/A
Analysts78.89
IPO05-31 2007-05-31
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

FOLD Daily chart

Company Profile

Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 484 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Company Info

AMICUS THERAPEUTICS INC

3675 Market Street

PHILADELPHIA PENNSYLVANIA 19104

P: 12159217600.0

CEO: John F. Crowley

Employees: 484

Website: https://www.amicusrx.com/

FOLD News

News Image21 hours ago - Amicus Therapeutics, Inc.Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
News Image21 hours ago - Amicus Therapeutics, Inc.Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...

News Image21 hours ago - Investor's Business DailyAmicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

News Image2 days ago - Seeking AlphaAmicus closes up 5% as it expects approval of Pompe disease therapy (NASDAQ:FOLD)

Amicus Therapeutics expects imminent approval of its Pompe disease treatment, AT-GAA, as indicated in an updated corporate presentation.

News Image9 days ago - Market News VideoAmicus Therapeutics (FOLD) Shares Cross Below 200 DMA
News Imagea month ago - Amicus Therapeutics, Inc.Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

FOLD Twits

Here you can normally see the latest stock twits on FOLD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example